Fujifilm plans to invest approximately JPY 9 billion yen ($83 million) to expand microbial production capacity of Fujifilm Diosynth Biotechnologies (FDB), its CDMO of biologics, vaccines and gene therapies. 

The expansion will triple FDB’s current capacity of microbial production at its site in Billingham, UK and is scheduled to be operational after 2022.

The expansion will include a new production line equipped with 2 X 2000-L fermenters and a modular purification suite. The utilities at the facility will be upgraded to accommodate for high-volume production.

Source: Fujifilm